Further multicenter prospective studies to confirm the findings of the present study in a broader spectrum of patients with PAH and to evaluate the relationship between the disease activities of PAH and increases in PTX3 are needed before PTX3 can be used routinely as a screening biomarker. Here, PTX3 is linked to pulmonary arterial hypertension.